Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

CHERTSEY, Angleterre, October 29, 2013 /PRNewswire/ --

Une infection à Clostridium difficile (ICD) est potentiellement fatale et dépasse le SARM en tant que cause principale de d'infections acquises en milieu hospitalier[1],[2]

L'European Society of Clinical Microbiology and Infectious Diseases (ESCMID) a publié de nouvelles directives recommandant la fidaxomicine pour tous les patients souffrant d'une ICD et pouvant suivre un traitement antibiotique par voie orale. Les directives recommandent spécifiquement la fidaxomicine en tant que traitement de première intention des patients ICD présentant une première récurrence ou un risque de récurrence et chez les patients souffrant de multiples récurrences d'ICD. Les directives recommandent également la fidaxomicine chez les patients souffrant de maladies graves et d'ICD non sérieuse.[3]

L'ICD est une des formes les plus courantes de diarrhée associées aux antibiotiques et les cas les plus graves peuvent entraîner des opérations des intestins voire un décès.[4] Les patients hospitalisés souffrant d'une ICD sont trois fois plus susceptibles de décéder en hôpital (ou un mois après l'apparition de l'infection) que ceux sans ICD.[5],[6] La récurrence est un problème majeur dans le traitement de l'ICD. 25 % des patients ICD souffrent d'une récurrence en l'espace d'un mois [7],[8],[9] et les patients qui ont déjà eu une récurrence courent un risque de 40 % d'un nouvel épisode d'ICD.[10]

« Un des problèmes les plus importants pour une gestion optimale de l'ICD est la récurrence. Par conséquent, la réduction considérable de la récurrence de la maladie avec DIFICLIR comparé à la vancomycine
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... August 2014: A new batteryless cardiac pacemaker based ... motion was presented at ESC Congress 2014 today ... does not require battery replacement. , Mr Zurbuchen, ... at ARTORG, University of Bern, Switzerland, said: "Batteries ... Once they reach a critically low energy level, ...
(Date:8/30/2014)... In a world where a typical response to conflict is ... a game app to teach another way. Launched in ... is a colorful way to encourage moral values playfully. ... double-duty by teaching players new ways to find happiness and ... for consistently taking the high road, the Ultimate Karma game ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... 30, 2014 The Truth about Six Pack ... will reveal to users some shocking foods that can burn ... in modeling looks, as well as some motivation secrets for ... that there is one unique trick that can help users ... despite what many people might think, cardio exercise routines are ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... age, they,often become forgetful and unsteady and may have ... need help recovering from an,injury or illness. Many don,t ... the familiar surroundings of home. The dilemma children,then face ... cared for without,placing them in an assisted living facility. ...
... to Play a Key Role as Governments and Civil Society ... Region Ponder Urgent Strategies to Tackle the Crisis, ... -- On World AIDS Day 2007, hundreds, perhaps thousands, of ... HIV in cities across,the Asia Pacific, becoming the latest statistics ...
... hip arthroplasty (THA), or hip replacement, is an ... have only followed patients for up to one ... issue of Arthritis Care & Research ( http://www.interscience.wiley.com/journal/arthritiscare ... years following hip replacement and found a long-term ...
... SAN FRANCISCO, Nov. 28 ECO2 Plastics, Inc.,(OTC ... eco-friendly,recycling company that is changing the way plastics ... that the Company,s,proprietary cleaning process can produce PET ... the manufacturing of food-contact containers., "Based upon ...
... Conseco, Inc. (NYSE:,CNO) said today that it has agreed to ... Group, Inc. (LTCG) for certain,back-office functions of the long term ... earlier this year that it was,considering this solution. Under the ... the customer call center and the ...
... -- There are estimated to be between ... with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune ... in their blood -- causing bruises, nosebleeds and, ... an international multicenter clinical research study led by ...
Cached Medicine News:Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Long-term improvement seen with hip replacement 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Hoffmann® II Hybrid External Fixation System ... generation in hybrid fixation. It incorporates ... and is designed to offer speed ... patented Hoffmann® snap-fit technology. , ,Using ...
Medicine Products: